US pharmacy compounding case could head to Supreme Court
This article was originally published in Scrip
A federal appeals court ruling upholding the USFDA's ability to regulate compounded medicines as new drugs has created different enforcement standards for compounding pharmacies throughout the country and could spur an appeal to the US Supreme Court to resolve the conflict.
You may also be interested in...
Under certain circumstances, potential clinical trial participants may be able to provide informed consent by writing on a blank piece of paper that they voluntarily agree to participate in a given protocol and texting or emailing a photo of the signed document to the investigator, US FDA says in latest guidance update.
Timelines in the CID program are tight, and sponsors should have a ‘fully baked’ trial design before heading into their first meeting with the agency, industry reps say; agency needs more simulation data from participating sponsors earlier and is working to ensure continuity for firms after the second of two meetings allowed under the program.
Oncology Center of Excellence’s Paul Kluetz says agency intends to explore the effects of decentralization, remote assessments and other approaches adopted mid-stream on safety evaluations, missing data and endpoint variability.